DK0941315T3 - Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner - Google Patents

Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner

Info

Publication number
DK0941315T3
DK0941315T3 DK97945684T DK97945684T DK0941315T3 DK 0941315 T3 DK0941315 T3 DK 0941315T3 DK 97945684 T DK97945684 T DK 97945684T DK 97945684 T DK97945684 T DK 97945684T DK 0941315 T3 DK0941315 T3 DK 0941315T3
Authority
DK
Denmark
Prior art keywords
antigen
relates
vaccines
induce
immune responses
Prior art date
Application number
DK97945684T
Other languages
English (en)
Inventor
Lee Mizzen
Lawrence S D Anthony
Original Assignee
Stressgen Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stressgen Biotechnologies Corp filed Critical Stressgen Biotechnologies Corp
Application granted granted Critical
Publication of DK0941315T3 publication Critical patent/DK0941315T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK97945684T 1996-11-26 1997-11-25 Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner DK0941315T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75662196A 1996-11-26 1996-11-26

Publications (1)

Publication Number Publication Date
DK0941315T3 true DK0941315T3 (da) 2006-05-15

Family

ID=25044309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97945684T DK0941315T3 (da) 1996-11-26 1997-11-25 Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner

Country Status (11)

Country Link
EP (1) EP0941315B1 (da)
JP (2) JP4484969B2 (da)
AT (1) ATE318899T1 (da)
AU (1) AU736318B2 (da)
CA (1) CA2272536A1 (da)
DE (1) DE69735376T2 (da)
DK (1) DK0941315T3 (da)
ES (1) ES2258796T3 (da)
HK (1) HK1022715A1 (da)
PT (1) PT941315E (da)
WO (1) WO1998023735A1 (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0700445T3 (da) 1993-06-04 2002-05-13 Whitehead Biomedical Inst Stressproteiner og anvendelser deraf
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6663868B1 (en) 1995-08-18 2003-12-16 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
BE1011033A6 (fr) * 1997-03-05 1999-04-06 Univ Bruxelles Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer.
US6709672B2 (en) 1997-03-05 2004-03-23 Biotech Tools S.A. Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction
CA2297786C (en) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
IL134341A0 (en) 1997-08-05 2001-04-30 Stressgen Biotechnologies Corp Compositions for inducing an immune response containing an hpv protein antigen
US7731972B1 (en) 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
CZ20002669A3 (cs) * 1998-01-23 2001-11-14 National Jewish Medical And Research Center Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest
EP2295065B1 (en) 1998-02-20 2013-10-09 The University of Miami Modified heat shock protein-antigenic peptide complex
DK1133517T3 (da) * 1998-11-24 2009-11-23 Bristol Myers Squibb Co Intranuklear målrettet transport af forbindelser ved hjælp af 70 kd varmeshock-protein
JP2003504074A (ja) 1999-07-08 2003-02-04 ストレスゲン バイオテクノロジーズ コーポレイション インビトロでのTh1様応答の誘導
AUPQ233799A0 (en) * 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US20020039583A1 (en) * 1999-09-30 2002-04-04 Subjeck John R. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1253939B1 (en) 2000-01-14 2009-08-05 Whitehead Institute For Biomedical Research In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent
IL153474A0 (en) 2000-06-26 2003-07-06 Stressgen Biotechnologies Corp Human papilloma virus treatment
JP5087201B2 (ja) 2000-08-03 2012-12-05 ジョンズ・ホプキンス・ユニバーシティ 抗原に小胞体シャペロンポリペプチドを連結した分子ワクチン
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
PL373675A1 (en) 2001-02-05 2005-09-05 Stressgen Biotechnologies Corporation Hepatitis b virus treatment
DK1536006T3 (da) 2002-08-30 2011-10-17 Medinet Co Ltd Cancerantigener og anvendelse deraf
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
EP1841785A2 (en) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
CA2632483C (en) 2005-12-06 2014-11-25 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved influenza vaccine
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
AU2007345768B2 (en) 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
MX2009008926A (es) * 2007-02-23 2009-09-14 Baylor Res Inst Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
JP2011513399A (ja) 2008-03-03 2011-04-28 ザ ユニバーシティー オブ マイアミ 同種癌細胞による免疫療法
WO2009117116A2 (en) 2008-03-20 2009-09-24 University Of Miami Heat shock protein gp96 vaccination and methods of using same
JP5917402B2 (ja) 2009-11-03 2016-05-11 タケダ ヴァクシーンズ, インコーポレイテッド キメラRSV−Fポリペプチド、およびレンチウイルスGagまたはアルファレトロウイルスGagに基づくVLP
US8685406B2 (en) * 2009-11-13 2014-04-01 The Board Of Regents Of The University Of Texas System Compositions of and method of using heat shock protein peptides
CN103687616A (zh) * 2011-07-21 2014-03-26 生物技术工具公司 Dnak制剂
MX2017010159A (es) 2015-02-06 2017-12-18 Heat Biologics Inc Vector que expresa conjuntamente vacunas y moléculas coestimuladoras.
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
KR101805430B1 (ko) 2017-04-26 2017-12-06 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
CA3230289A1 (en) * 2021-08-30 2023-03-09 Japan Eco-Science Co., Ltd. Immunostimulatory preparation and cosmetic, food, feed additive, and quasi-pharmaceutical product containing the immunostimulatory preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0700445T3 (da) * 1993-06-04 2002-05-13 Whitehead Biomedical Inst Stressproteiner og anvendelser deraf
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
US6663868B1 (en) * 1995-08-18 2003-12-16 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren

Also Published As

Publication number Publication date
AU5112098A (en) 1998-06-22
WO1998023735A1 (en) 1998-06-04
ATE318899T1 (de) 2006-03-15
AU736318B2 (en) 2001-07-26
ES2258796T3 (es) 2006-09-01
JP2008214360A (ja) 2008-09-18
PT941315E (pt) 2006-06-30
DE69735376T2 (de) 2006-12-14
JP2001504702A (ja) 2001-04-10
HK1022715A1 (en) 2000-08-18
DE69735376D1 (de) 2006-04-27
EP0941315A1 (en) 1999-09-15
JP4484969B2 (ja) 2010-06-16
CA2272536A1 (en) 1998-06-04
EP0941315B1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
DK0941315T3 (da) Fusionsproteiner indeholdende stressproteiner til induktion af immunreaktioner
DK0587780T4 (da) Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
DK1584685T3 (da) Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1090039T3 (da) Peptidsammensætning som immunogen til behandling af allergi
BRPI0815578B8 (pt) peptídeos, agentes farmacêuticos compreendendo os mesmos, métodos in vitro para induzir uma célula apresentadora de antígeno, usos dos referidos peptídeos, e vacina
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
NO20081043L (no) Vaksine for fisk
ATE389397T1 (de) Adjuvante zusammensetzungen
EP4226938A3 (en) Coronavirus vaccine
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2023147092A3 (en) Coronavirus vaccine
DK1397380T3 (da) Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
DE69739233D1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
BRPI0309787E2 (pt) Polipeptídeo isolado, composição de vacina anti-carrapato de espécies múltiplas, molécula de cdna isolada, vetor de expressão, célula isolada, vacina anti-carrapato de espécie múltipla, e, método de induzir uma resposta imune em um mamífero contra a infestação de carrapato de espécie múltipla e seus patógenos associados
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof